Related Experiment Videos
Essential fatty acids in Alzheimer's disease
F M Corrigan1, A Van Rhijn, D F Horrobin
1Argyll and Bute Hospital, Lochgilphead, Scotland.
Annals of the New York Academy of Sciences
|January 1, 1991
Summary
Essential fatty acids (EFAs) supplementation improved Alzheimer's disease symptoms more than placebo. This study investigated EFA treatment in Alzheimer's patients, showing greater benefits with EFA therapy.
Area of Science:
- Neuroscience
- Biochemistry
- Clinical Nutrition
Background:
- Alzheimer's disease (AD) is linked to abnormal essential fatty acid (EFA) levels in plasma and red blood cell phospholipids.
- EFAs play crucial roles in brain health and neuronal function.
Purpose of the Study:
- To evaluate the efficacy of EFA supplementation, combined with antioxidants, in patients with Alzheimer's disease.
- To compare the therapeutic effects of EFAs against a placebo in an AD patient cohort.
Main Methods:
- A 20-week, double-blind, placebo-controlled trial involving 36 patients diagnosed with Alzheimer's disease.
- Participants were randomized to receive either EFAs plus antioxidants or a placebo.
Main Results:
- Both the EFA and placebo groups demonstrated improvement in their condition after 20 weeks.
- The degree of clinical improvement was consistently more significant in the group receiving EFA supplementation.
Conclusions:
- Supplementation with essential fatty acids and antioxidants shows promise as a therapeutic strategy for Alzheimer's disease.
- EFA treatment offers superior benefits compared to placebo for improving outcomes in Alzheimer's patients.